IBDEI1XN ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30873,1,3,0)
 ;;=3^Acute nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,30873,1,4,0)
 ;;=4^N00.8
 ;;^UTILITY(U,$J,358.3,30873,2)
 ;;=^5015499
 ;;^UTILITY(U,$J,358.3,30874,0)
 ;;=N00.9^^123^1597^10
 ;;^UTILITY(U,$J,358.3,30874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30874,1,3,0)
 ;;=3^Acute nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,30874,1,4,0)
 ;;=4^N00.9
 ;;^UTILITY(U,$J,358.3,30874,2)
 ;;=^5015500
 ;;^UTILITY(U,$J,358.3,30875,0)
 ;;=N01.0^^123^1597^69
 ;;^UTILITY(U,$J,358.3,30875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30875,1,3,0)
 ;;=3^Rapidly progr neph synd w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,30875,1,4,0)
 ;;=4^N01.0
 ;;^UTILITY(U,$J,358.3,30875,2)
 ;;=^5015501
 ;;^UTILITY(U,$J,358.3,30876,0)
 ;;=N01.1^^123^1597^68
 ;;^UTILITY(U,$J,358.3,30876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30876,1,3,0)
 ;;=3^Rapidly progr neph synd w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,30876,1,4,0)
 ;;=4^N01.1
 ;;^UTILITY(U,$J,358.3,30876,2)
 ;;=^5015502
 ;;^UTILITY(U,$J,358.3,30877,0)
 ;;=N01.2^^123^1597^66
 ;;^UTILITY(U,$J,358.3,30877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30877,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,30877,1,4,0)
 ;;=4^N01.2
 ;;^UTILITY(U,$J,358.3,30877,2)
 ;;=^5015503
 ;;^UTILITY(U,$J,358.3,30878,0)
 ;;=N01.3^^123^1597^64
 ;;^UTILITY(U,$J,358.3,30878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30878,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,30878,1,4,0)
 ;;=4^N01.3
 ;;^UTILITY(U,$J,358.3,30878,2)
 ;;=^5015504
 ;;^UTILITY(U,$J,358.3,30879,0)
 ;;=N01.4^^123^1597^63
 ;;^UTILITY(U,$J,358.3,30879,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30879,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,30879,1,4,0)
 ;;=4^N01.4
 ;;^UTILITY(U,$J,358.3,30879,2)
 ;;=^5015505
 ;;^UTILITY(U,$J,358.3,30880,0)
 ;;=N01.5^^123^1597^67
 ;;^UTILITY(U,$J,358.3,30880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30880,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,30880,1,4,0)
 ;;=4^N01.5
 ;;^UTILITY(U,$J,358.3,30880,2)
 ;;=^5015506
 ;;^UTILITY(U,$J,358.3,30881,0)
 ;;=N01.6^^123^1597^62
 ;;^UTILITY(U,$J,358.3,30881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30881,1,3,0)
 ;;=3^Rapidly progr neph synd w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,30881,1,4,0)
 ;;=4^N01.6
 ;;^UTILITY(U,$J,358.3,30881,2)
 ;;=^5015507
 ;;^UTILITY(U,$J,358.3,30882,0)
 ;;=N01.7^^123^1597^65
 ;;^UTILITY(U,$J,358.3,30882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30882,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,30882,1,4,0)
 ;;=4^N01.7
 ;;^UTILITY(U,$J,358.3,30882,2)
 ;;=^5015508
 ;;^UTILITY(U,$J,358.3,30883,0)
 ;;=N01.8^^123^1597^70
 ;;^UTILITY(U,$J,358.3,30883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30883,1,3,0)
 ;;=3^Rapidly progr neph synd w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,30883,1,4,0)
 ;;=4^N01.8
 ;;^UTILITY(U,$J,358.3,30883,2)
 ;;=^5015509
 ;;^UTILITY(U,$J,358.3,30884,0)
 ;;=N01.9^^123^1597^71
 ;;^UTILITY(U,$J,358.3,30884,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30884,1,3,0)
 ;;=3^Rapidly progr neph synd w/ unsp morphologic changes
